

Brixadi Enrollment Form

Fax Referral To: 1-800-323-2445 | Phone: 1-855-524-2566 | Email Referral To: Customer.ServiceFax@CVSHealth.com

Six Simple Steps to Submitting a Referral		
PATIENT INFORMATION (Patient must complete high	ghlighted area) Scheduled Injection Date:	
Patient Name:	Address: Gender: Male Female : Email:	
City, State, ZIP Code:	DOB: Last Four of SSN: Gender: 🗌 Male 🗌 Female	
Primary Phone: Alternate Phone	:Email:	
By providing the phone number(s) and email address above, you are consenting prescription(s), account and health care. Standard data rates apply. Message	ng to receive automated calls, emails and/or text messages from CVS Specialty® about your	
Designated Patient Contact By signing below Lauthorize my Contact listed below to rec	ceive logistical and administrative information related to my treatment,	
	will remain liable, regarding delivery of Brixadi (buprenorphine extended-	
, ,	u(s) made by the Contact or actions taken in reliance on such Contact	
decisions. Please list any authorized Contact as set forth abo		
	Relationship:Phone:	
Patient's Signature:	Date:	
Patient Authorization		
my Brixadi prescription medication for the sole purpose of a appointment. I understand that my signature below serves a outreach/contact me and/or my designated contact on this	provider, on my behalf, to coordinate the delivery, receipt and storage of dministration by my prescribing provider at my next scheduled is the Patient Ship Authorization, which means the pharmacy will not form, prior to shipping medication except in certain circumstances.** ent or coinsurance amount, up to a total amount of \$50, without prior	
	_	
Patient's Authorization:	Date:	
available to Medicare and Medicaid patients because government payors are	e patient's copay/coinsurance responsibility is greater than \$50. Enrollment above is not excluded from this offering. Copayment, copay or coinsurance means the amount a member is eductible, a percentage of the prescription price, a fixed amount or other charge, with the	
2 PRESCRIBER INFORMATION		
Facility Type: Private Practice Outpatient Hospital	/Clinic Inpatient Facility Correctional	
	escriber's Last Name:	
	#:DEA#:	
	Practice NPI#:	
	City:	
	r:Fax Number:	
Office Contact Name: Contact's Phone:		
Note: The pharmacy will only ship to the address registered with the DEA, associated with the DEA# provided above.		
_	rescription/medical insurance cards with this form, front and back)	
Is the Patient Insured? Yes No Is the Patient enrolle		
Policy Holder's Name:	Policy Holder's DOB: Relationship to Patient: one: Policy ID: Group #:	
Medical Insurance: releph	one: Policy ID: Group #:	
Policy ID: Group #:	Prescription Plan Telephone: RX BIN #: RX PCN #:	
Check hav if nationt is appulled in manufacturer copay as	sistance If yes, please provide ID#	
2 DIAGNOSIS AND CLINICAL INFORMATION (to		
	as patient previously been treated for Opioid Use Disorder? \Box Yes \Box No	
If YES, list all previous medications:		
List concomitant medications (e.g., adjunctive depression medications)	cations, sedative hypnotics, psychostimulants):	
Die	gnosis (ICD-10):	
F11.2 Opioid dependence	F11.24 With opioid-induced mood disorder	
F11.2 Opioid dependence	F11.24 With opioid-induced mood disorder F11.25 Opioid dependence with opioid-induced psychotic disorder	
F11.20 Opioid dependence, uncomplicated F11.21 Opioid dependence, in remission	F11.28 Opioid dependence with other opioid-induced disorder	
F11.22 Opioid dependence with intoxication	F11.29 With unspecified opioid-induced disorder	
F11.23 Opioid dependence with withdrawal	Other Code: Description:	

Brixadi Enrollment Form

5 PRESCRIPTION INFORMATION (to be completed by prescriber only)

Because of the risk of serious harm or death that could result from intravenous self-administration, **Brixadi is only available through** a restricted program called the Brixadi Risk Evaluation and Mitigation Strategy (REMS) Program. Health care settings and pharmacies that order and dispense Brixadi must be certified in this program and comply with the REMS requirements. Brixadi should only be prepared and administered by a licensed health care provider.

NOTE: Prescriber must comply with his/her state-specific prescription requirements such as state-specific prescription forms, electronic prescribing requirements, product substitution or any other prescription element which may be required and that is not captured by this form. For this reason, the prescription form below should only be used if permitted by the applicable law in your state. The prescriber should include all required elements of a controlled substance prescription.

Patient Name (First and Last):	Patient Date of Birth:	
Patient Address:		
Drug Name, Strength, and Dosage Form:		
Directions/Sig:		
	tten):Refills	
	Prescriber Phone Number:	
Prescriber DEA #: State License #:		
Prescriber Address:		
	Supervising Physician Phone Number:	
Supervising Physician Address:	Supervising Physician DEA#:	
6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)		
May Substitute/ Product Selection Permitted / Substitution Permissible	Dispense As Written/ Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute	
Prescriber's Signature: Date:	Prescriber's Signature: Date:	
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution"		
ATTN: New York and Iowa providers, please submit electronic prescription		

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

I have obtained written authorization from the Patient to disclose the Patient's personal health information and any other information on this enrollment form as may be required to comply with all applicable federal and state laws and regulations, including, but not limited to, the HIPAA Privacy Rule (45 C.F.R. Parts 160 and 164) and the Confidentiality of Substance Use Disorder Patient Records Regulation (42 C.F.R. Part 2), as amended from time to time.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates